SCHEMBL20070060

SCHEMBL20070060

CC(C)CC(=O)NC1(CO)CCN(C(C)C)CC1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TNKS2 Q9H2K2 2/20 0.34
TNKS O95271 1/20 0.34
PARP1 P09874 1/20 0.34
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
GAA P10253 1/20 0.31
SIGMAR1 Q99720 1/20 0.31
RET P07949 1/20 0.31
MMP1 P03956 1/20 0.30
MMP9 P14780 1/20 0.30
MMP13 P45452 1/20 0.30
HCN4 Q9Y3Q4 2/20 0.30
MME P08473 1/20 0.30
CCR1 P32246 1/20 0.30
HCN1 O60741 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20070061 0.86 SMN1; SMN2 (0.41) TP53SMN1; SMN2TNKS2TNKSPARP1
SCHEMBL20147486 0.84 RET (0.41) TP53SMN1; SMN2TNKS2TNKSPARP1
SCHEMBL20205901 0.83 TP53 (0.39) TP53SMN1; SMN2ALDH1A1KDM4EGAA
SCHEMBL20147518 0.82 RET (0.40) TP53SMN1; SMN2TNKS2TNKSPARP1
SCHEMBL20147467 0.81 TP53 (0.38) TP53SMN1; SMN2TNKS2TNKSPARP1
SCHEMBL20147508 0.80 RET (0.42) TP53SMN1; SMN2TNKS2ALDH1A1KDM4E
SCHEMBL20147488 0.79 RET (0.42) SMN1; SMN2ALDH1A1L3MBTL1RET
SCHEMBL21451678 0.74 CYP2D6 (0.35)
SCHEMBL20147549 0.70 RET (0.42) RET
SCHEMBL20147524 0.70 RET (0.43) SMN1; SMN2ALDH1A1RETHCN4HCN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
WO-2018071454-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 TP53 759/4885SMN1; SMN2 646/4885TNKS2 2698/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 TP53 759/4885SMN1; SMN2 646/4885TNKS2 2698/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 TP53 759/4885SMN1; SMN2 646/4885TNKS2 2698/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 TP53 759/4885SMN1; SMN2 646/4885TNKS2 2698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.